Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by MirrorWorldManon Mar 16, 2023 11:21pm
154 Views
Post# 35344184

RE:RE:RE:RE:RE:News Release: Further information…

RE:RE:RE:RE:RE:News Release: Further information…I read closely the details of 1year $5M credit facility from Pivot. The repayment terms are brutal, including an immediate repayment of $1M after an offering or equity investment, 15% interest rate, $1M Guarantor requirements and 2.5 M x .10 warrants. That is a desperate bridge financing and tremendous anticipation of revenue within one year. It is highly unlikely that Marc Edwards, averse to diluting as he is, would be able to raise $5 M + 15% interest to pay back that loan by issuing shares on the open market. Its a big gamble and the chips are down. Question is do we double down?
<< Previous
Bullboard Posts
Next >>